Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Goetz on Survival Data With CDK4/6 Inhibitors in Breast Cancer

January 23rd 2019

Matthew P. Goetz, MD, chair of the Breast Cancer Disease-Oriented Group and co-leader of the Women’s Cancer Center at the Mayo Clinic, discusses survival data with CDK4/6 inhibitors in patients with hormone receptor-positive breast cancer.

FDA Issues Complete Response Letter for Sacituzumab Govitecan in TNBC

January 18th 2019

The FDA has issued a complete response letter to Immunomedics regarding its biologics license application for sacituzumab govitecan as a treatment for patients with metastatic triple-negative breast cancer who have received at least 2 prior therapies, citing chemistry, manufacturing, and control matters.

FDA Issues Letter Regarding Safety Concerns With Paclitaxel-Coated Devices

January 18th 2019

The FDA has issued a letter to healthcare providers that they should monitor patients with a type of peripheral arterial disease who have been treated with vascular balloons that were coated with paclitaxel or stents that release paclitaxel in the femoropopliteal artery in the leg.

Dr. Shao on Managing Toxicity With Neratinib in HER2+ Breast Cancer

January 16th 2019

Theresa Shao, MD, assistant professor of medicine, hematology and medical oncology, Icahn School of Medicine, Mount Sinai Medical Center, discusses managing toxicities associated with neratinib (Nerlynx) in patients with HER2-positive breast cancer.

Chemoimmunotherapy in TNBC: The KEYNOTE-355 Trial

January 15th 2019

Questioning CDK4/6 Inhibitor Cross-Resistance in HR+ mBC

January 15th 2019

Antibody-Drug Conjugates in TNBC: Sacituzumab Govitecan

January 15th 2019

Combining PARP and Checkpoint Inhibitors in TNBC

January 15th 2019

Chemoimmunotherapy in TNBC: The IMpassion130 Trial

January 15th 2019

Moving CDK4/6 Inhibition to HER2+ Breast Cancer

January 15th 2019

HER2+ Breast Cancer: Neratinibs Role as Adjuvant Therapy

January 15th 2019

Making Sense of Adjuvant Therapy in HER2+ Breast Cancer

January 15th 2019

HR+ Metastatic Breast Cancer: Upfront CDK4/6 Inhibition

January 15th 2019

Current State of CDK4/6 Inhibition in HR+ mBC

January 15th 2019

Pathologic Complete Response in HER2+ Breast Cancer

January 15th 2019

HER2+ Breast Cancer: Use of Weekly Paclitaxel-Trastuzumab

January 15th 2019

HER2+ Breast Cancer: The KATHERINE Trial

January 15th 2019

A Background on Early HER2+ Breast Cancer

January 15th 2019

Dr. Albain Discusses Race-Based Breast Cancer Study Within TAILORx

January 15th 2019

Kathy S. Albain, MD, director, Breast Clinical Research Program, co-director, Breast Oncology Center, professor of medicine, Stritch School of Medicine, Loyola University Chicago, discusses a race-based study within the TAILORx trial.

Expert Explores Future of CDK4/6 Inhibitors in Breast Cancer

January 11th 2019

Matthew P. Goetz, MD, discusses the impact of CDK4/6 inhibitors and their future role in the treatment of hormone receptor–positive breast cancer.